BRANFORD, Conn., Dec. 20, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at Biotech Showcase 2025 being held January 13-15, 2025 in San Francisco. Details of the presentation are as follows: Event: Biotech Showcase 2025 Date and Time:  January 13, 2025 at 3:00 p.m., PT Location: Hilton San Francisco Union Square (Yosemite C) Partic ...

Exhibit 99.1 Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates BRANFORD, Conn. — Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: ● Completed a follow-on offering of $10 million in gross proceeds ● Dosed first Netherton syndrome pat ...

BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update.Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceeds Dosed first Netherton syndrome patient with ATR-12 Submitted an IND to the FDA and received IND cleara ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other juri ...

Exhibit 99.1 Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates BRANFORD, Conn. — Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights ● Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other jurisdict ...

Azitra (NYSEMKT:AZTR) stock is falling hard on Wednesday morning after the biopharmaceutical company’s shares underwent a massive rally yesterday.Azitra stock is down 75.2% as of Wednesday morning. That comes with some 6.3 million shares of the stock traded. For the record, the company’s daily average trading volume is about 1.3 million shares.Yesterday’s trading saw the tock close out normal hours up 206.8%. That came with more than 75 million shares of AZTR stock changing hands. Unfortunately for investor ...

Azitra (NYSEMKT:AZTR) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents.This covers the company’s filaggrin-secreting strain of Staphylococcus epidermidis. A patent was issued to it on July 16 U.S. Patent and Trademark Office (USPTO). That includes future potential pipeline candidates for indications including atopic dermatitis.On top of this, Azitra announced three newly allowed patents in the U.S., Canada, and China. The U.S. pate ...

Exhibit 99.1 Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates BRANFORD, Conn. — Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update. Q1 2024 and Recent Business Highlights ● Advanced ATR-12's Phase 1b trial, activating sites, advancing central IRB approval, and identifying init ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | --- | |----------------- ...